243 related articles for article (PubMed ID: 19373040)
1. Repositioning HIV protease inhibitors as cancer therapeutics.
Bernstein WB; Dennis PA
Curr Opin HIV AIDS; 2008 Nov; 3(6):666-75. PubMed ID: 19373040
[TBL] [Abstract][Full Text] [Related]
2. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
[TBL] [Abstract][Full Text] [Related]
3. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.
Gantt S; Casper C; Ambinder RF
Curr Opin Oncol; 2013 Sep; 25(5):495-502. PubMed ID: 23872785
[TBL] [Abstract][Full Text] [Related]
4. The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir.
Subeha MR; Telleria CM
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33228205
[TBL] [Abstract][Full Text] [Related]
5. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.
Plastaras JP; Vapiwala N; Ahmed MS; Gudonis D; Cerniglia GJ; Feldman MD; Frank I; Gupta AK
Cancer Biol Ther; 2008 May; 7(5):628-35. PubMed ID: 18285707
[TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
Gupta AK; Cerniglia GJ; Mick R; McKenna WG; Muschel RJ
Cancer Res; 2005 Sep; 65(18):8256-65. PubMed ID: 16166302
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.
Gills JJ; Lopiccolo J; Dennis PA
Autophagy; 2008 Jan; 4(1):107-9. PubMed ID: 18000394
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
9. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
10. Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
Allegra A; Innao V; Allegra AG; Pulvirenti N; Pugliese M; Musolino C
Oncol Rep; 2020 Jun; 43(6):1729-1736. PubMed ID: 32236596
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
Pyrko P; Kardosh A; Wang W; Xiong W; Schönthal AH; Chen TC
Cancer Res; 2007 Nov; 67(22):10920-8. PubMed ID: 18006837
[TBL] [Abstract][Full Text] [Related]
12. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
13. The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.
Meier-Stephenson V; Riemer J; Narendran A
Onco Targets Ther; 2017; 10():2581-2593. PubMed ID: 28553123
[TBL] [Abstract][Full Text] [Related]
14. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.
Gupta AK; Li B; Cerniglia GJ; Ahmed MS; Hahn SM; Maity A
Neoplasia; 2007 Apr; 9(4):271-8. PubMed ID: 17460771
[TBL] [Abstract][Full Text] [Related]
15. Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.
Goda JS; Pachpor T; Basu T; Chopra S; Gota V
Indian J Med Res; 2016 Feb; 143(2):145-59. PubMed ID: 27121513
[TBL] [Abstract][Full Text] [Related]
16. HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.
Hruz PW
Curr Opin HIV AIDS; 2008 Nov; 3(6):660-5. PubMed ID: 19373039
[TBL] [Abstract][Full Text] [Related]
17. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
18. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
19. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Patick AK; Boritzki TJ; Bloom LA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
